Covid Information

November 30, 2022

Resources and Medical Information Sites

Treatment Protocols

Spike Detox Protocols


Recent Studies- where to find

Disclaimer

- This is not medical advice.
- People should always consult with their medical provider before starting any medical treatment.
- Everyone needs to do their own research and be sure it has multiple credible resources. Information is constantly changing.

RESOURCES Where to Find Information?

GLOBAL DATA: Covid -19 Deaths per Million, November 26, Coronavirus (COVID-19) Deaths - Our World in Data



Patent Information for Coronavirus

Reiner Fuellmich Interviews Dr David Martin: Patents, Vaccines and the Coronavirus Scenario... (bitchute.com)

- 1st vaccine, Pfizer, Jan. 28, 2000; Patent # 6372224, for canine coronavirus; S-spike protein;
- April 19th, 2002, the NIAID built an infectious replication defective coronavirus. It was specifically <u>targeted for human lung epithelium</u>.
- <u>US Patent 7279327</u>, lays out in very specific gene sequencing, the ACE-2 binding domain, the S-1, spike protein, and other could be synthetically modified in the laboratory, <u>National Institute of Allergy and Infectious Diseases</u>

Patent Information


- April 25, 2003: <u>CDC</u> files patent #7220852 with 2 parts: #46592703p and #776521, covered Coronavirus gene sequence and the <u>MEANS to DETECT</u> the virus through RTPCR. <u>Own both the corona virus and its detection.</u>
- CDC has final approval of Patent in 2007 after numerous appeals

• The gene sequence that is filed by CDC in 2003, again in 2005, and then again in 2006, 89-99% of the sequence overlaps that have been identified in what is called the novel subclade of SARS COV-2.


MASK Resource: Dr. Stephen Petty:

Petty Podcasts (rumble.com)

Mask studies done with duck tape, superglue, and steel lab tabletops



V-SAFE Phone App, CDC Datahttps://icandecide.org/



Resources of Information

- CDC Coronavirus Disease 2019 (COVID-19) | CDC
 - Side effects that happen within 7 days of getting vaccinated are common but are mostly mild.
- Pfizer Documents: 8 pages of adverse events
 - reissue_5.3.6-postmarketing-experience.pdf (phmpt.org)
 - Pfizer Documents Analysis Archives DailyClout

Pfizer Documents

- U.S. District Judge Mark T. Pittman's decision on January 6 to deny the request from the FDA to suppress the data for the next 75 years, which the agency claimed was necessary, in part, because of its "limited resources."
- When Pfizer applied for FDA approval, they were aware of almost 158,000 adverse events.
- <u>Pfizer Covid vaccine has 1,291 side effects reveals official documents Children's Health Defense Pennsylvania Chapter</u> (childrenshealthdefense.org)

Pfizer Documents

- Starts on page 30
- The list includes acute kidney injury, acute flaccid myelitis, anti-sperm antibody positive, brain stem embolism, brain stem thrombosis, cardiac arrest, cardiac failure, cardiac ventricular thrombosis, cardiogenic shock, central nervous system vasculitis, death neonatal, deep vein thrombosis, encephalitis brain stem, encephalitis hemorrhagic, frontal lobe epilepsy, foaming at mouth, epileptic psychosis, facial paralysis, fetal distress syndrome.

Resource Organizations

- Front Line Covid Critical Care Alliance, FLCCC -GLOBAL (covid19criticalcare.com) GUIDE BOOK
- <u>I-PREVENT-COVID-Protection-Protocol.pdf</u> (covid19criticalcare.com) The I-PREVENT protocol must be part of an overall strategy that includes common sense public health actions such as good hand hygiene, avoiding crowded public gatherings, adequate ventilation, and other measures. The following protocol can be used for both chronic and post-exposure prevention.
 - POST-EXPOSURE instructions
- <u>I-CARE-Protocol-Sept-6v2-1.pdf</u> (covid19criticalcare.com) A Guide to Early Treatment of COVID-19 It is critical to recognize that infection with SARS-CoV-2, the virus that causes COVID-19, progresses through a number of stages and phases. <u>Treatment is therefore highly stage-specific</u>. COVID-19 is a clinical diagnosis


Weekly talks

VAERS

- The Vaccine Adverse Event Reporting System (VAERS) was created and implemented in 1990 by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC)
- to receive reports about adverse events that may be associated with vaccines.
- The primary purpose for maintaining the database is to serve as an early warning or signaling system for adverse events not detected during pre-market testing.

Myocarditis in VAERS

A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse
 Events Reporting System (VAERS) in Association with COVID-19
 Injectable Biological Products (substack.com)



HOW BAD IS MY BATCH?

https://howbadismybatch.com

<u>Craig Paardekooper</u> Kingston University, London


Analyzed Data from EMA (FDA)
Then analyzed data from the US;

U.S. Vaccine Adverse Event Reporting System (VAERS) data shows 9,500 different Batches in the US in 2021

ADR: Adverse Reaction: includes all symptoms

SAE: Severe Adverse Event: ER, Hospitalization, Disability, Death.

Death Reports by Batch Number Death is usually related to # of vaccinated



Resources Continued

- American Association of Physicians and Surgeons, AAP (aapsonline.org)
- Dr. McCullough: <u>Dr. Peter A. McCullough, MD, MPH</u> (petermcculloughmd.com)
- Children's Health Defense (childrenshealthdefense.org)
- Americas Frontline Doctors (americas frontline doctors.org)
- V-Safe ICAN Informed Consent Action Network (icandecide.org)
 - CDC Data from phone app of vaccinated

Treatment Protocols

FLCCC I-Prevent <u>I-PREVENT-COVID-Protection-Protocol.pdf</u> (covid19criticalcare.com)

Ivermectin: 0.2 mg/kg – start treatment with one dose, take second dose 48 hours later, then 1 dose every 7 days (weekly). Best taken with a meal or just following a meal, for greater absorption.

Zinc: 30-40 mg daily. Zinc supplements come in various forms (e.g., zinc sulfate, zinc citrate and zinc gluconate).

Melatonin: Begin with 1 mg and increase as tolerated to 6 mg before bedtime (causes drowsiness). Slow- or extended-release formulations preferred.

Mouthwash: three times a day. Gargle three times a day (do not swallow) with an antiseptic-antimicrobial mouthwash containing chlorhexidine, cetylpyridinium chloride (e.g., Scope™, Act™, Crest™) or povidone-iodine.

I-Prevent Protocol – Get your Vit D level checked

- Steam inhalation: once a day. Inhaled steam supplemented with antimicrobial essential oils (e.g., Vicks VapoRub™ inhalations)
- Vitamin D: dosing varies (see tables below). Vitamin D supplementation is likely a highly effective (i.e., the elderly, obese, people of color, and those living in northern latitudes).
 - The target is over 50 ng/ml; at this level the risk of dying from COVID-19 is extremely reduced.
 - See protocol for additional

I-RECOVER-AN-APPROACH-TO-TREATING-LONG-COVID.pdf (covid19criticalcare.com)

- Prednisone: Ivermectin: Low dose naltrexone (LDN):
- Intermittent daily fasting and/or periodic daily fasts: Fasting promotes autophagy, the body's protective mechanism to remove misfolded, foreign and damaged proteins.
- NOTE: Hydroxychloroquine inhibits autophagy and should be avoided in patients undergoing intermittent fasting.
- Resveratrol: These compounds have been demonstrated to augment autophagy.
- Melatonin:
- Vitamin D:
- Omega-3 fatty acids:
- Aspirin: 81 mg daily.
- Curcumin (turmeric): 500 mg twice daily.

World Council for Health



• Spike Protein Detox Guide — World Council for Health

This is an evolving guide with emerging information on how to clear viral and vaccine-induced spike proteins from the body.

The lists of herbal and other medicines and supplements have been compiled in a collaboration between international doctors, scientists, and holistic medical practitioners.

World Council for Health-Top 10 Detox Essentials

- Vitamin D
- Vitamin C
- NAC (N-acetylcysteine)
- Ivermectin
- Nigella seed
- Quercetin
- Zinc
- Magnesium
- Curcumin
- Milk thistle extract

Variants

- Omicron evolved out of South Africa (initially called BA.1)
- BA5: Emerged out of Japan and is still the dominant variant in the world.
- United States, seeing new variants of
 - BQ.1.1 = 5 % of total cases
 - XBB.1 = 0.5% of current cases

Nov-2-Weekly-Webinar-slides-combined.pdf (covid19criticalcare.com)


New Variants:

BQ.1.1 and

XBB.1

In the United States:


- BQ.1.1 5% of cases
- XBB.1 less than 0.5%





Most Recent Studies

- COVID-19 early treatment: real-time analysis of 2,316 studies (c19early.org)
 - Look at by diet, meds, effective, costs
 - COVII All studies (pooled effects, all stages) c19early.org Nov 2022 studies



ACTIV-6

- Test for effective EARLY Treatment for Acute Illness: Usually start treatment ASAP, weight based, provide all data for review
 - Test medication was mailed-taking up to weeks to start
 - Testing of "asymptomatic" participants, no illness confirmed.
 - Dosing was limited to <200 lbs, 40% were underdosed
 - Goal was to measure for symptoms, hospitalization at 7 and 14 days
 - Final measurement was changed from 7 > 14 > 28 days
 - End result: Test medication was not "effective" in reducing symptoms or hospitalization at 28 days.

ACTIV-6 & New COVID-19 Variants

Nov-2-Weekly-Webinar-slides-combined.pdf (covid19criticalcare.com)

National Institutes <u>Of</u> Health ACTIV-6 Trial Studying Ivermectin

Research

JAMA | Original Investigation

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

A Randomized Clinical Trial

Susanna Naggie, MD, MHS; David R. Boulware, MD, MPH; Christopher J. Lindsell, PhD; Thomas G. Stewart, PhD; Nina Gentile, MD; Sean Collins, MD, MSci; Matthew William McCarthy, MD; Dushyantha Jayaweera, MD; Mario Castro, MD, MPH; Mark Sulkowski, MD; Kathleen McTigue, MD, MPH, MS; Florence Thicklin; G. Michael Felker, MD, MHS; Adit A. Ginde, MD, MPH; Carolyn T. Bramante, MD, MPH; Alex J. Slandzicki, MD; Ahab Gabriel, MD; Nirav S. Shah, MD, MPH; Leslie A. Lenert, MD, MS; Sarah E. Dunsmore, PhD; Stacey J. Adam, PhD; Allison DeLong, BS; George Hanna, MD; April Remaly, BA; Rhonda Wilder, MS; Sybil Wilson, RN; Elizabeth Shenkman, PhD; Adrian F. Hernandez, MD, MHS; for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators



QUESTIONS